3 terminated. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 3 |
| Phase 2 | 2 | Terminated 2 |
Follow ATG: new trials by email Literature Review of ATG trials Research Report on ATG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ATG Plus Low-dose PT-Cy for GVHD Prevention Cyclophosphamid, ATG - Hematologic Malignancy | Phase 3 | Terminated | Peking University People's Hospital | 66 | 2023-11-01 | 2025-06-03 |
| T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Stem Cell Transplant, Myeloablative conditioning regimen - Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders | Phase 2 / Phase 3 | Terminated | Masonic Cancer Center, University of Minnesota | 22 | 2000-09-01 | 2018-01-23 |
| Stem Cell Transplantation for Hematological Malignancies Stem Cell Transplant, Busulfan, Cyclophosphamide - Leukemia, Lymphocytic, Acute, AML | Phase 2 / Phase 3 | Terminated | Masonic Cancer Center, University of Minnesota | 11 | 2000-06-07 | 2017-12-05 |
Hematologic Neoplasms (2) · Chediak-Higashi Syndrome (1) · Hematologic Diseases (1) · Histiocytosis, Langerhans-Cell (1) · Immune System Diseases (1) · Lymphohistiocytosis, Hemophagocytic (1) · Lymphoproliferative Disorders (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Masonic Cancer Center, University of Minnesota (2) · Peking University People's Hospital (1)
United States (2) · China (1)
Angela Smith, MD (1) · Margaret MacMillan, MD (1)